Transparency Review November 2022
Author - CMS |
Published - 2022
“The lack of transparency in the functioning of the regulatory system is a major problem. Even basic information is not available, like names of medicines licensed for marketing and manufacture in India, brands of medicines in India and MRPs, names of manufacturers, list of vendors and manufacturers of bulk drugs and other ingredients going into a medicine. There is no way of knowing why certain drugs are approved again after being banned, and proceedings of committees which ban or approve them. The first step to solve the problem is to acknowledge that it exists and to bring complete transparency in the functioning of all healthcare regulatory agencies.”
